COMMUNIQUÉS West-GlobeNewswire
-
La Croix-Rouge canadienne et Walmart Canada donnent le coup d’envoi à la campagne de financement annuelle
25/06/2026 -
Vaxart Announces Update to BARDA Funding Award to Reflect Current Scope of COVID-19 Oral Pill Vaccine Trial
25/06/2026 -
Aeroflow Health Acquires Canopie to Close the Maternal Care Gap for Millions of New Mothers
25/06/2026 -
Atalan Launches Nurse Retention Platform Designed to Identify Risk Up to 12 Months in Advance
25/06/2026 -
TRUE-See Selected to Participate in Microsoft for Start-Ups Azure AI Program to Accelerate Innovation and Growth
25/06/2026 -
BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™
25/06/2026 -
Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering
25/06/2026 -
Canadian Red Cross and Walmart Canada launch annual giving campaign
25/06/2026 -
The LaVie Institute Introduces Less-Invasive Breast Augmentation Technique with Rapid Recovery
25/06/2026 -
Milestone Scientific Strengthens Board to Support Next Phase of Growth
25/06/2026 -
Conexeu Sciences Opens Vancouver R&D Facility to Advance Regenerative Tissue Platform
25/06/2026 -
Data Presented on Two-Year Proximal Neck Dynamics from First-in-Human Study of Abdominal Aortic Aneurysm Treatment
25/06/2026 -
DeepHealth Receives Two FDA Clearances Enabling it to Add Cardiovascular Insights and Prior Exam Integration to its AI-Powered Breast Suite
25/06/2026 -
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
25/06/2026 -
Herantis appoints experienced drug development expert Dr Juha Savola as Chief Medical Officer
25/06/2026 -
Leads Biolabs Announces Partner Oblenio Bio’s $62 Million Oversubscribed Series B Financing to Advance Tri-Specific T-Cell Engager LBL‑051 for Autoimmune Diseases into Clinical Development
25/06/2026 -
Un nouveau projet de l’ACE pour soutenir les ergothérapeutes diplômés à l’étranger au Canada
25/06/2026 -
ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
25/06/2026 -
Oblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development
25/06/2026
Pages